prognostic significance of her2, p53, ki67, mvd-cd34, cox2, mmp7, and vimentin in gastric cancer

Background: gastric cancer (gc) patients have a poor prognosis mainly due to late diagnosis. we aimed to study the prognostic effects of various biomarkers, including her2, cd34, p53, ki67, cox2, mmp7, and vimentin in gc. methods: we performed immunohistochemistry (ihc) to examine the expression of potential biomarkers in 140 gc patients. cd34 protein expression was quantified to assess angiogenesis through scoring microvessel density (mvd). we used a multivariable cox-proportional hazard model to estimate hazard ratios (hrs) representing the prognostic role of the biomarkers and the clinicopathological parameters. results: patients diagnosed at the advanced tumor stage exhibited a significantly higher risk of mortality than those diagnosed at the early stages (hr = 5.96, ci: 3.73 – 9.51). we also observed higher risks of mortality in patients with high mvd-cd34 (hr = 5.35, ci: 2.36 – 12.12), her2-positive (hr = 2.82, ci: 1.69 – 4.37), p53-positive (hr = 4.03, ci: 2.53 – 6.4), high ki67 (hr = 4.34, ci: 2.64 – 7.13), high cox2 (hr = 4.77, ci: 2.39 – 9.49), high mmp7 (hr = 2.75, ci: 1.53 – 4.94), and high vimentin (hr = 3.78, ci: 1.7 – 8.39) tumors compared to their corresponding reference groups. the association was statistically significant for her2, p53, ki67, cox2, and mvd-cd34 among those diagnosed in an early stage. conclusion: overall, evaluation of tumor biomarkers in gc patients can result in more precise estimates of prognosis, especially in early-stage tumors. these biomarkers could potentially be considered for targeted therapy of gc patients to improve their survival.